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The persistence and variability of 188 Haemophilus influenzae isolates in respiratory
tract of 30 cystic fibrosis (CF) patients during a long period of time (March 1994 to
February 2001) was studied. Serotyping, biotyping, antibiotic susceptibility testing,
DNA fingerprinting and analysis of outer membrane protein (OMP) profiles were
performed in all isolates. A total of 115 distinct pulsed field gel electrophoresis (PFGE)
restriction profiles were identified. Ninety per cent of patients were co-colonized with
two or more H. influenzae clones over the studied period. A third of the patients were
cross-colonized with one or two H. influenzae strains; 11% of the clones persisted 3 or
more months. Biotype, outer membrane protein profiles and resistance profiles showed
variation along the studied period, even in persisting clones. Interestingly, 4 isolates
(2.1%) recovered from 3 patients were type f capsulate, three of them belonging to the
same clone. ß-lactamase production was detected in 23.9% of isolates while 7% of the
ß-lactamase negative isolates presented diminished susceptibility to ampicillin (ß-
lactamase negative ampicillin resistance phenotype). Remarkably, 21.3% of the H.
influenzae isolates presented decreased susceptibility to ciprofloxacin, which were
mainly observed in persisting clones. Of the H. influenzae isolated from CF patients, 18
(14.5%) exhibited a mutator phenotype in comparison with 1 (1.4%) from non-CF
patients (p < 0.0001). Ten patients (33.3 %) were colonized by hypermutable strains
over the study period. Moreover, multiresistance phenotype and long term clonal
persistence were significantly associated, in some cases, for up to seven years. Despite
of dynamic situation of H. influenzae bronchial colonization in CF patients, these results
suggest the persistence of better adapted (more resistant?) H. influenzae clones.
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INTRODUCTION
Cystic fibrosis (CF) is an autosomal recessive disorder resulting from mutations in a
gene on the long arm of chromosome 7 (11). The gene product is the cystic fibrosis
transmembrane conductance regulator (CFTR), which regulates and facilitates transport
of electrolytes across epithelial cell and other membranes (10).
Haemophilus influenzae is regularly involved in chronic lung infections and acute
exacerbations of CF patients (26). To better study the persistence of this bacteria several
typing methods have been applied: serotyping, biotyping, outer membrane protein
electrophoresis (OMP) and genotyping methods as random PCR (1, 17, 18, 35).
On the other hand, long-term antibiotic therapy is widely used for the treatment of
lung infection in CF patients. The risk of development of antibiotic resistance in these is
clearly higher than in other patients, and that also applied for H. influenzae (17). The
first ciprofloxacin-resistant H. influenzae strains in Spain were recovered from cystic
fibrotic patients, and studied by our groups (4, 9).
The goals of the present study were to carry out a prospective follow up of CF patients
over time, to determine: i) whether these patients maintained the same H. influenzae
strains or were subsequently colonized by different strains; ii) to study the antimicrobial
susceptibility profiles in comparison non-CF patients; and iii) to discern if antimicrobial
resistance and persistence were associated. Since other studies showed high proportions
of hipermutable strains in CF patients carrying Pseudomonas aeruginosa (22) and
Staphylococcus aureus (25), we decided to study if a similar trend may occur in the case
of Haemophilus influenzae strains.
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MATERIALS AND METHODS
Patients. During the period 1994-2001, thirty CF patients (20 males and 10 females)
with a history of Haemophilus influenzae infections were identified at three different
hospitals of Spain (Ramón y Cajal from Madrid, Lozano Blesa from Zaragoza, and
Virgen de las Nieves from Granada). The dynamics of Haemophilus influenzae
colonization in all these patients were studied for a mean period of median 3,4 years
(range 1-6.7 years).
Bacterial isolation. Bacterial isolates were recovered from respiratory secretions,
most of them expectorated sputum specimens during scheduled assessment or
pulmonary exacerbations.. Samples were homogenized with N-acetyl-cysteine and
processed by a modified quantitative technique (38). Columbia 5% blood, MacConkey,
mannitol-salt, and a selective Burkholderia cepacia agar media were incubated on air
for 24 h at 37 ºC plus 24 h at 25 ºC. In addition, bacitracin-chocolate agar was plated
and incubated on 5 % CO2 for 48 h. at 37 ºC. A culture was considered positive for H.
influenzae when growth of this organism was observed, irrespectively of the bacterial
count.
Bacterial identification and Biotyping. The isolates were identified as Haemophilus
influenzae on the basis of the following biological characteristics: gram-negative small
rods requiring X and V factors for growth (Mast Diagnostics, Merseyside, U.K). All
the strains were serotyped by a co-agglutination test (Phadebact Haemophilus Test,
Boule Diagnostics AB, Huddinge, Sweden) including both specific anti-type b
antibodies and a pool of specific antitype a, c, d, e, and f antibodies. Discrimination
among these serotypes was done with specific a to f antisera obtained in our laboratory,
and eventually confirmed by the PCR technique (7). To evaluate whether the initial H.
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influenzae population isolated from patients could be composed by a mixture of
different strains, we selected 9 individual colonies from 11 samples and carried out a
complete bacterial identification for each one of them.
The presence of a mutator phenotype was studied in 124 H. influenzae isolates
comprising the 111 different PFGE patterns (four more were excluded as their rifampin
MICs were  4.0 g/ml), and all the 13 OMP variants obtained from the sputum of 30
CF patients. As a control group for the susceptibility and hipermutability studies, a
collection of 188 epidemiologically unrelated H. influenzae isolates and 71 from non-
CF patients matched by time of isolation, geographical source and anatomical origin
were also studied. Biotyping was performed according to the method described by
Kilian (12).
Outer membrane proteins profiles. An overnight culture of Haemophilus influenzae
was collected in 10 ml of 10 mM HEPES buffer (pH 7.5), and the suspension was
subjected to sonication. Cellular debris was removed by centrifugation at 26,450 x g for
3 min (3000 g for 10 min). The supernatant was then removed and centrifuged at 26,450
x g for 90 min at 4 ºC. The pellet containing the cell membrane material was re-
suspended in HEPES buffer and sodium lauryl sarcosylate (2% in HEPES buffer) for 10
min. Each preparation was then centrifuged at 26,450 x g for 60 min at 4ºC. The
resulting pellet was diluted in distilled water to a concentration of 1,400 µg of protein
per ml. Solutions were then stored at –70 ºC until all samples were processed. Twenty-
five microliters of each membrane suspension were added to 50 µl of sample buffer
containing 50 % distilled water, 12.6 % 0.5 M Tris-HCl (pH 6.8), 10.5 % glycerol, 21 %
sodium dodecyl sulfate (SDS) (10 % solution), and 5% bromophenol blue (0.1%
solution). The final solution was boiled for 5 min. Samples were loaded onto SDS-
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polyacrylamide (4% stacking gel and 10 % separating gel), prepared, and run according
to the method of Laemmli (13).
Pulsed-field gel electrophoresis (PFGE). Total DNA was prepared and PFGE was
performed as described previously (14). The restriction endonucleases Sma I and Bsp
120 I (Apa I) (MBI, Fermentas, Vilnius, Lithuania) were used at the manufacturer´s
suggested temperature. Restriction fragments were separated by PFGE in agarose 1%
gel in 0.5 X TBE buffer (45 mM Tris, 45 mM boric acid, 1.0 mM EDTA, pH 8.0) with
the BioRad CHEF Mapper apparatus, Hercules, California, U.S.A.). The initial pulse
time of 5 s was increased linearly to 50 s over 23.3 h at 6 V/cm at 13 ºC.  ladders were
applied as molecular size markers, size 48.5-1000 kb (PFGE Marker I- Boehringer-
Mannheim, Germany). Gels were then stained with ethidium bromide and
photographed under ultraviolet light. Fragment patterns were compared visually and
interpreted by the software (MVSP Shareware). Similarity analysis and dendrograms
were done with this database system on the basis of molecular mass patterns.
Antimicrobial susceptibility testing. For antibiotic susceptibility screening
purposes, the disk diffusion susceptibility test for H. influenzae was performed on
standard Haemophilus test medium to the following antibiotics: ampicillin, amoxicillin-
clavulanic acid, cefaclor, cefixime, cefuroxime, cefotaxime, sulphamethoxazole-
trimethoprim, chloramphenicol, tetracycline, kanamycin, rifampin, ciprofloxacin and
nalidixic acid. The isolates were classified as susceptible, intermediate or resistant
according to the criteria of the NCCLS (20). Minimal inhibitory concentration (MIC)
was determined by the Epsilon-test (E-test) method including the following antibiotics:
ampicillin, amoxicillin-clavulanic, cefotaxime, sulphametoxazole-trimethoprim,
chloramphenicol, ciprofloxacin and nalidixic acid. The control strains were H
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influenzae ATCC numbers: 49247 and 51907. ß-lactamase activity was studied by the
chromogenic cephalosporin test with nitrocephin as the substrate.
Determination of mutation frequencies. To determine mutation frequencies, one
bacterial colony was resuspended in 20 ml of Brain-Heart Infusion Broth (BHI) and
grown at 37ºC with 5% CO2 overnight. Bacterial cells were then collected at 3,000 rpm
for 5 min and re-suspended in 1 ml of BHI. A 100 l sample from this suspension as
well as from successive dilutions was plated onto Haemophilus-Test-Medium (HTM)
with and without rifampin (10 g/ml). After 48 h of incubation, the number of colonies
was counted, and the mutation frequencies were determined as its relative proportion to
the total count of viable organisms plated. For every strain yielding > 30 colonies on
antibiotic containing medium, the experiment was repeated in triplicate, and results
were indicated as a mean. A strain was considered to have a mutator phenotype when
the mutation frequency was higher than 10-7, i.e., at least ten times higher than the
average mutation frequency found for H. influenzae strains in non-cystic fibrosis
patients (22, 25).
Analysis of the results. Management of data and statistical calculations were carried
out using the Whonet Programme (WHO/CSR/DRS/99.1, World Health Organization).
Mean mutation frequencies were compared by the Mann-Whitney Test; categorical




Frequency and Density of Haemophilus influenzae colonization. 794 sputum
specimens from 30 CF patients were analysed (median 26,5, range 4-82 per patient).
The median follow-up was 40,8 months (range 12 - 80). In total, 188 H. influenzae
strains were obtained (mean number of isolates per patient 6,3, range 1-27) from the 30
patients studied (Table 1). In the group of eleven clinical patients (see Materials and
Methods) in which nine independent H. influenzae colonies were studied, only one
clonal type was identified per patient, suggesting that co-colonization is a rare event in
our series. The quantitative study in the sputa showed a CFU / ml average of 108 (range,
103 -109). The cross-colonising clones persisting for more that 3 months did not reached
higher cell densities in the sputa than the total average (7.7 x 107 and 9.1 x 107,
respectively).
Serotypes and Biotypes. Four (2.1%) of the 188 isolates were serotype f, three of them
belonging to the same clone, despite being isolated from three different patients. The
remaining 184 strains, from 27 patients, were nontypable. The most frequent biotype
was biotype II (30.3%) followed by biotypes I (27.7%), III (17%), V(10.6%), VI
(6.4%), VII (3.7%), VIII (2.7%) and IV (1.6%). Removing duplicate strains
(considering only the first isolate of each clone) the most frequent biotype was II
(36.5%), followed by the biotypes III (25.2%), I (21.7%), V (6.1%), VI (3.5%), VII
(3.5%), IV (1.7%) and VIII (1.7%). Six (5,2%) out of the 115 H. influenzae clones
obtained as defined by the PFGE profile (see below) showed biotype changes in
successive isolations in the same patient.
PFGE-typing profiles. On the basis of the PFGE patterns, using Sma I as restriction
enzyme, we obtained 112 different profiles from 188 isolates; three strains were non-
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digested with Sma I but they were digested with Bsp 120 I . The same number was
assigned to identical restriction patterns obtained from different strains. PFGE patterns
with coefficients of similarity greater that 85% were considered to define to a particular
clone. For instance, PFGE patterns 1A and 1 B (Table 1) were considered the same
clone 1 according to the Tenover criteria (31). We also tested the isolates with other
restriction enzyme (Bsp 120 I), obtaining the same clonal distribution (Fig. 1, 2, 3 ). In
some cases, strains with the same PFGE profile had a variation in their OMP profile;
hence, we designed them with lower case letters next to the numbers of the PFGE
pattern (Table 1 and Fig. 5).
Persistence
The 115 H. influenzae PFGE patterns persisted in average 2.5 months (range 1-80).
Thirteen PFGE patterns (11.3%) persisted for 3 or more months in their respective
patients. In several patients, H. influenzae strains with indistinguishable PFGE patterns
persisted during a long period of time (Table 1). Figures 1,2 and 3 show the
colonization course in three selected patients: 1, 3 and 28. In 24 patients (80%), the
first strain of H. influenzae was isolated only once, being replaced by other strains in
subsequent cultures. In 27 patients (90%), two or more different strains were isolated
over the period of study.
Thirteen (11.4%) of the 114 clones (115 PFGE patterns) suffered OMP
variations (Table 1 and Fig. 4); the greatest number of OMP variants was found in
patient 3. In patients 14, 15 and 16, with long follow-up periods (33 to 50 months),
only one H. influenzae strain was isolated (Table 1).
Cross-colonizing strains.
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Five clones were isolated from more than one single patient: Clone 19 was isolated
from patients 6 and 7 the same month (Table 1), persisting one month in the last patient.
Clone 39 colonized patients 8 and 14. Clone 41 was found in patients 8, 9 and 12.
Clone 52 was obtained from patients 13, 16 and 20. Clone 70 (a type f isolate)
colonized patient 20 during one month and 2.5 years later appeared in patient 21 (table
1). In total 10 patients were cross-colonized with one or two strains from other patients.
However, strains from patients sharing identical clones did not always present the same
biotype: the biotype of clone 19 was IV in patient 6 but was II in patient 7; the biotype
of clone 52 was II in patient 12 but was VIII in patient 16.
Antibiotic susceptibility. Among the 188 H. influenzae strains, diminished ampicillin
susceptibility was found in 29.2 %; 23, 9% produced ß-lactamase and 5.3 % presented
diminished susceptibility (MIC ≥2 µg/ml) to ampicillin (β-lactamase negative ampicillin 
resistance (BLNAR)-phenotype). Considering only the first isolate of each one of the
different 115 clones, the corresponding figures are 29.6 % for ampicillin reduced
susceptibility, 26.1 % for beta-lactamase production and 3.5 for BLNAR (Table 2). All
isolates were susceptible to cefotaxime, cefixime, amoxycillin-clavulanate. Only one
strain was beta-lactamase-positive amoxicillin/clavulanate-resistant (BLPACR)
Regarding the ciprofloxacin susceptibility, 40 (21.3%) of the 188 H. influenzae
isolates had MICs >1 µg/ml in comparison with 9 (7.8%) from 115 first isolates of each
PFGE pattern (p = 0. 002).
According to NCCLS breakpoints (20), chloramphenicol and amoxicillin-
clavulanate exhibited susceptibility rates equal to or higher than 85%. The antibiotics
with the lowest intrinsic activity (as measured by MIC90) were trimethoprim-
sulfamethoxazole and ampicillin, both displaying an MIC90 ≥ 32 µg/ml.
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Eleven (36.7 %) patients were colonized by multiple resistant H. influenzae
clones (defined as resistance or diminished susceptibility to three or more antimicrobials
of different antibiotic classes). The most common combinations of multidrug resistance
were: ampicillin, cefaclor, chloramphenicol, ciprofloxacin and cotrimoxazol. Only
three patients (5,9 and 10, Table 1) were colonized by totally antibiotic susceptible
strains.
Antibiotic resistance and H. influenzae persistence. Of the 13 PFGE patterns (11.3
%, 12 clones) that persisted for at least three months, three did not change its
antimicrobial susceptibility over time; three acquired additional antibiotic resistance
markers, three lost at least one resistance, and four suffered apparent changes in
sensitivity. The most frequently acquired resistance determinants were tetracycline in
six PFGE patterns, and kanamycin in three PFGE patterns. Of the 12 clones that
persisted for more than three months, 4 had diminished susceptibility to two or more
antibiotics and persisted for 1,545 days (51.5 months; range 15-80) on average,
compared with a period of 291 days (9.7 months; 3-26) for the 8 more susceptible
persistent clones (p = 0.0001, Fisher´s exact test).
Twenty-three patients (76.7 %) yielded at least three consecutive H. influenzae
strains, irrespectively of their clonality. In four (13.3 %) patients no changes were
observed in the antibiotic susceptibility patterns; in six patients (20 %) the isolates
increased their antibiotic resistance markers; in five (16.7 %) the isolates diminished its
antibiotic resistance. In three (10 %) the strains initially increased its antibiotic
resistance but it decreased further on; in two (6.7 %) the strains initially lost resistance
determinants but they increased afterwards; and in three (10 %) there was a continuous
fluctuation in their antibiotic susceptibility. Older patients (patient 1, 37 years; patient 2,
18 years and patient 28, 20 years at the beginning of the study) were colonized with
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more strains resistant to different antibiotics such as ciprofloxacin (nalidixic acid),
cotrimoxazol, chloramphenicol, ampicillin and cefaclor.
Antibiotic susceptibility of CF patients strains versus non-CF patients control
strains. We observed a significantly higher frequency of resistance to ampicillin
(55/188, 29.2%) and decreased susceptibility to ciprofloxacin (40/188, 21.2%) among
cystic fibrosis patients than among the patients of the control group (39/188, 20.7% and
0% respectively) (Table 3). Similarly, a significant higher proportion of BLNAR
(10/188, 5.3%) and resistance to two or more antibiotics (62/188, 32.9%) were found in
the strains from the CF group in comparison with the non-CF control strains (20/188,
10.6%) (Table 3).
Frequency of hypermutation. Of the H. influenzae isolated from CF patients, 18
(14.5%) exhibited a mutator phenotype, compared with one (1.4%) from non-CF
patients (p = 0.002). 10 patients (33.3 %) were colonized by hypermutable strains over
the study period. The mutation frequency distributions are shown in Fig. 5. The mean
mutation frequency in the two groups (3.4 x 10-7 for 124 strains in the CF group and
1,22 x 10-8 in 71 strains in the non-CF group) significantly differed (p<0.0001, Mann-
Whitney U test). Two groups of isolates from CF patients were distinguished: a group
of non-mutators, with a mean mutation frequency of 2.4  2.5 x 10-8, and a group of
mutators, with a mean mutation frequency of 2.2  4.9 x 10-6 (Fig. 5). The mutation
frequency of the only mutator strain in non-CF patients was 1,9 x 10-7; the remaining
strains had a low mutation frequency (mean: 9.7 x 10-9  1.4 x 10-8) (Fig. 5).
Of the 18 hypermutable strains, 16 presented resistance to one of more antibiotics
(seven were multiple-antibiotic resistant, one was resistant to ampicillin and co-
13
trimoxazol, five were resistant to co-trimoxazol, two to tetracycline, one to ampicillin)
and two were fully antibiotic-susceptible.
DISCUSSION
Several studies have previously investigated the epidemiology of long term
Pseudomonas aeruginosa colonization in the respiratory tract of patients with CF, but
there are a limited number of studies dealing with H. influenzae (17, 18, 26). We
describe here the dynamics of H. influenzae colonization in 30 CF patients over a long
period of time (median 40.8 months, range 12-80 months), a longer time than in the
only previous study (18). Sequential isolates were obtained in 27 patients. Only in 20 %
of the patients the same clone was repeatedly recovered during the time of observation.
This proportion was identical using PFGE (this study) or RAPD-typing (18).
As other authors (17, 37), we observed that all biotypes are recognized among
H. influenzae isolates from CF patients. In our series, the order of biotype isolation by
frequency (considering first isolate of each PFGE clones) was II (36%) III (25%), I
(21%) followed by V, VI, VII and VIII (in total 17 %). These proportions are almost
identical to those found in the Netherlands, with the exception of biotype VIII, hyper-
represented in the Möller series (17). As these authors, we have also observed biotype
fluctuations among persistent and cross-colonizing clones. No apparent association
between biotypes and outer membrane protein profiles was found, in accordance with
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previous observations (2). Nevertheless, as biotypes, variations over time were observed
in persisting clones (Table 1), corroborating the low power as typing marker of this
technique (34).
In our study, only three patients kept all their strains totally susceptible to the
antimicrobials studied. We have observed greater antibiotic susceptibility figures among
the 115 first isolates of each PFGE pattern (114 clones) than in the total 188 H.
influenzae isolates, suggesting that persistence increases the levels of resistance. The
usual ciprofloxacin MIC of H. influenzae is ≤ 0,03 µg/ml (23). We have shown that H.
influenzae strains with MIC ≥ 0.12 µg/ml present target mutations (9). It is noteworthy
that the number of strains with a ciprofloxacin MIC > 1.0 µg/ml in our study increased
from 7.8% in the 115 first isolates to 21.3% in all 188 isolates. The two most persistent
clones (clone 1 from patient 1, which persisted 80 months and clone 101 from patient
28, which persisted 72 months) presented a high MIC for ciprofloxacin (4).
The large proportion of strains with diminished susceptibility (MIC > 1,0 µg/ml) to
ciprofloxacin (21.3 %) in our study is noteworthy, and the highest reported to date in the
literature for H. influenzae from any geographical or clinical location. Note that the
overall frequency of ciprofloxacin resistance in H. influenzae in Spain do not exceed 0.1
% (16).
Interestingly, the rate of ampicillin-resistance in our CF H. influenzae isolates,
although higher than in the Netherlands (Möller 1998), was almost identical (29.2 %) to
the average frequency of ampicillin-resistance in Spain (30.1 %) (16). BLNAR isolates
from CF were more abundant among persistent strains (5.3%) than among the first
isolated strains of each clone (3.5%).
In general, this study suggests that CF H. influenzae strains are much more
antibiotic-resistant than strains from non-CF patients. Resistance to two or more
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antimicrobials occurred in 62 (32.9%) of all H. influenzae isolates (Table 3) and 11
(36.7%) of patients; analogous observations have made for other bacterial pathogens,
such as P. Aeruginosa, S. Maltophilia, and S. Aureus (22, 25, 32). The increased
resistance rates in these patients have been associated with high and persistent
consumption of antimicrobial agents (15). However, the effect of high rates of
consumption on the frequency of antibiotic resistance is expected to be significantly
amplified in the presence of hypermutable (mutator) bacteria.
Our measurements of mutation frequency corroborated in H. influenzae the
tendency of a significant proportion (14.5%) of hypermutable strains previously found
in CF patients with Pseudomonas (19.5%) (22) and Staphylococcus aureus (14.6%). It
has been shown that hypermutation strongly correlates with antibiotic resistance (22),
and this probably also occurs with H. influenzae. It is to note that the mechanisms of
resistance derived from mutational events in H. influenzae (such as ciprofloxacin-
resistance and co-trimoxazol) are more influenced by hypermutation than those
mediated by horizontal gene transfer (such as beta-lactamases). We cannot rule out the
possibility that hypermutation may originate other selective advantages related to the
adaptation and survival in the local conditions of the CF lung.
Mutation frequency (Fig. 5) was less polarized in H. influenzae than in
Pseudomonas and similar to the Staphylococcus, with a wide range of distribution.
Van Schilfgaarde et al (36) suggested that penetration of H. influenzae between
epithelial cells in vivo might contribute to the persistence of this microorganism in CF
patients in the presence of antibiotics and antibodies, despite the fact that the isolated
bacteria are fully susceptible to these antibacterial activities in vitro. Besides of this, it
does appear that the prolonged microbial colonization / infection that is characteristic of
the CF lung results from defects in the innate or non-specific immune system (10).
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H. influenzae cross-infection with five clones among ten different patients was
observed. This could be due to close contact among these patients, and/or that these
clones have an special ability to invade the respiratory tract. One of these five clones
was serotype F. Non-encapsulated H. infuenzae isolates are almost always from CF
patients, although encapsulate serotype b may be occasionally isolated, most often from
CF children less than 5 years of age. In our study, with the exception of four type f
isolates all H. influenzae were nontypeable. To the best of our knowledge, this is one of
the first CF studies to isolate capsulated type f strains. In other research of our
laboratory (3), with different type of patients, we found 18 strains of serotype f in a total
of 38 respiratory samples from 1996 to 2000, suggesting that serotype f strains often
colonize the upper respiratory tract.
In summary, using PFGE typing we characterized 115 genotypes among 188 isolates of
H. influenzae, in 30 CF patients over a long follow up ranging from one to seven years.
Although persistence of the same clone was only observed in nearly 12% of patients,
chronic colonization with multiple H. influenzae clones was observed in the majority of
patients. Interestingly, antimicrobial resistance was associated with strains persistence
over long periods of time.
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TABLE 1 Results of typing of 188 Haemophilus influenzae strains isolated from 30 patients with cystic fibrosis at three different hospitals of Spain
















pattern pattern (mo) variants
(years/month
s)
1 M 37yr / 10mo 80 mo 15 1A/1B/2 10/4/1 80/15/0 1Aa,1Ab,1Ac
VI(6), VIII(2), VII(2)-VI-
VI
2 F 18yr / 11mo 39 mo 3 3/4 2/1 39/0 VII-V
3 F 12yr / 4mo 41 mo 18 5/6/7/8 14/2/1/1 26/10/0/0
5a(5), 5b,
5c(4)/6a V-III-II-III
4 M 4yr / 3mo 58 mo 7 9/10/11/12/13 1/2/1/1/2 0/3/0/0/2 II-I-I-II-I
5 M 15yr / 9mo 60 mo 3 14/15 2/1 1/0 II-III


















8 M 11yr / 2mo 41 mo 3 39/40/41 1/1/1 II-III-II
9 M 21yr / 5mo 12 mo 3 41/42/43 1/1/1 III-III-II
10 F 16yr / 8mo 49 mo 2 44/45 1/1 I-II
11 M 11yr / 9mo 48 mo 3 46/47/48 1/1/1 II-II-I
12 M 1yr / 6mo 37 mo 6 49/41a/50/51/52/53 1/1/1/1/1/1 41 a VIII-II-VII-III-II-II
13 M 5yr / 9mo 51 mo 5 52 a/54/55/56 1/2/1/1 0/1/0/0 52 a II-III-II-II
14 F 8yr / 11mo 33 mo 1 39 1 II
15 M 18yr / 1mo 50 mo 1 57 1 I
16 F 6yr / 7mo 41 mo 1 52 1 VIII
17 F 5yr / 10mo 48 mo 7 58/59/60/61/62 2/1/1/1/2 9/0/0/0/6 II-V-I-III-II
18 M 4yr / 10mo 40 mo 4 63/64/NT/65 1/1/1/1 I-II-III-I
19 M 22yr / 6mo 28 mo 2 66/67 1/1 IV-III
20 F 3yr / 8mo 38 mo 9 68/69/70/71/72/73 1/2/2/1/2/1 0/11/1/0/2/0 72a III-II-I-V-III-II
21 M 1yr / 2mo 47 mo 7 74/75/76/77/78/79/70 1/1/1/1/1/1/1 I-III-V-III-II-II-I
22 F 5yr / 8mo 16 mo 5 80/81/82/83 1/1/1/2 0/0/0/2 83a II-II-II-VII, II
23 M 2yr / 3mo 40 mo 7 84/85/86/87/88/89 1/2/1/1/1/1 0/2/0/0/0/0 III-II-III-II-II-I
24 M 20yr / 2mo 19 mo 2 90/91 1/1 III-III
25 M 3mo 17 mo 2 92/93 1/1 II-III
26 M 9yr / 7mo 23 mo 3 94/95/96 1/1/1/1 II-II-II
27 M 5yr / 6mo 14 mo 5 NT/97/98/99/100 1/1/1/1/1 III-V-II-II-III
28 M 20yr / 9mo 72 mo 27 101/102/103/104/105 23/1/1/1/1 72/0/0/0/0 101a I(20), II(2), IV(1)-I-I-I-II
29 M 2yr / 5mo 25 mo 3 106/107/108 1/1/1 VII-VI-I
30 M 6yr / 5mo 20 mo 4 109/110/111 2/1/1 11/0/0 I-I-I
1A, 1B. Clone 1 subtypes.
Lower case letters. OMPs variants.
Bold type. Cross-colonizing strains.
(*) Refers to total number of isolates
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TABLE 2. Minimal inhibitory concentrations (MIC) of Haemophilus influenzae isolated












256 0.50 64 0.886
115
0.064-
256 0.25 64 0.82
Amoxicillin/Clavulanic
-acid 188 0.064-8 0.5 2 0.555
115 0.064-4 0.5 2 0.472
Cefotaxime 188 0.003-2 0.23 0.125 0.029
115 0.003-1 0.016 0.06 0.022
Chloram-phenicol 188
0.125-
16 0.5 8 0.692
115
0.125-
16 0.5 1.0. 0.534
Co-trimoxazol 188
0.012-
64 4 64 1.807
115
0.012-
64 4 32 0.903
Ciprofloxacin 188
0.003-
64 0.012 4 0.042
115
0.003-
32 0.012 0.025 0.019
1 Two figures are specified; first (188), is the total number of isolates; second (115), is
the number of PFGE patterns.
2 Expressed in µg/ml.
26
TABLE 3. Antimicrobial susceptibility comparison between H. influenzae strains




(188 strains) (188 strains)
Nº fully antibiotic-susceptible 88 50 0.006
Nº chloramphenicol-resistant 23 36 0.12
Nº with ciprofloxacin MIC >
1µg/ml2 0 40 <0.0001
Nº amoxicillin/clavulanic acid-
resistant 1 4 0.37
Nº trimethoprim-sulfamethoxazole-
resistant 68 123 0.001
Nº ß-lactamase + 38 45 0.54
Nº BLNAR3 1 10 0.01
Resistance to 2 or more
antimicrobials 20 62 <0.0001
1 Fisher’s exact test.
2 Usual ciprofloxacin MIC in H. influenzae  is ≤ 0.03 µg/ml (23). 
3BLNAR, beta-lactamase-negative-ampicillin-resistance.
FIG. 1. PFGE fingerprints of 15 strains from patient 1 in chronological order. The
patient harbors 3 patterns: pattern 1A (lanes 1, 3, 5, 6, 10, 11, 12, 13, 14 and 15), pattern
1B (lanes 2, 4, 7 and 8) and pattern 2 (lane 9). Pattern 1B strains showed the same
biotype (VI) as six strains (lanes 1, 3, 5, 6, 11 and 15) of the pattern 1A and the pattern
27
2 (lane 9). In panel A are shown the Sma I-PFGE fingerprints. In panel B the Bsp 120 I
(Apa I)-PFGE fingerprints. M is the molecular size marker (PFGE marker).
FIG. 2. PFGE fingerprints of 18 strains from patient 3 in chronological order. The
patient harbors 4 clones: clone 4 (lanes 1,2,3,4,5,6,7,8,9,10,11,12, 13 and 16) , clone 6
(lanes 14 and 18), clone 7 (lane 15) and clone 8 (lane 17). Clones 6 and 8 showed the
same biotype (III). In panel A are shown the Sma-PFGE fingerprints. In panel B the Bsp
120I (Apa I)-PFGE fingerprints. M is the molecular size marker (PFGE marker). PFGE
patterns of the same strains with Bsp 120 I (Apa I), in the second photo.
FIG. 3. PFGE fingerprints of 27 strains from patient 28 in chronological order. The
patient harbors 5 clones: clone 101 (lanes 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
17, 19, 20, 21, 24, 25, 26 and 27), clone 102 (lane 5), clone 103 (lane 18), clone 104
(lane 22) and clone 105 (lane 23). Three strains of the clones 102 (lane 5), 103 (lane 18)
and 104 (lane 22), and twenty strains (lanes 1, 2, 3, 4, 6, 7, 8, 9, 11, 12, 13, 14, 16, 17,
19, 20, 21, 24, 25 and 26) of the clone 101 showed the same biotype (I). Clone 105 and
two isolates of the clone 101 (lanes 10 and 27) showed the same biotype (II). In panel
A are shown the Sma-PFGE fingerprints. In panel B the Bsp 120I (Apa I)-PFGE
fingerprints. M is the molecular size marker (PFGE marker).
FIG 4. Variants of Outer membrane protein profiles of seven H. influenzae strains
belonging to two PFGE patterns (1A and 1B) from patient 1 and isolated in different
periods of time. Letters a and b indicate variations in the OMPs.
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Figure 5. Mutation frequency of the CF H. influenzae and non-CF H. influenzae strains
on rifampin. Each dot represents the mean mutation frequency calculated from 3
experiments for 1 strain. Most strains in both groups yielded mutation frequencies to
rifampin resistance <10-7. Strains with mutation rates >10-7 were considered to be
displaying an hypermutable phenotype.
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